JAMP PRUCALOPRIDE TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

PRUCALOPRIDE (PRUCALOPRIDE SUCCINATE)

Доступна з:

JAMP PHARMA CORPORATION

Код атс:

A06AX05

ІПН (Міжнародна Ім'я):

PRUCALOPRIDE

Дозування:

2MG

Фармацевтична форма:

TABLET

Склад:

PRUCALOPRIDE (PRUCALOPRIDE SUCCINATE) 2MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

15G/50G

Тип рецепту:

Prescription

Терапевтична области:

MISCELLANEOUS GI DRUGS

Огляд продуктів:

Active ingredient group (AIG) number: 0153049002; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2019-12-09

Характеристики продукта

_ JAMP PRUCALOPRIDE_
_Page 1 of 37_
PRODUCT MONOGRAPH
PR
JAMP PRUCALOPRIDE
Prucalopride Tablets
1 mg and 2 mg prucalopride as prucalopride succinate
Prokinetic agent
Jamp Pharma Corporation
1310 rue Nobel,
Boucherville,
Québec, J4B 5H3
Date of Preparation:
October 28, 2019
Submission Control No: 226302
_ JAMP PRUCALOPRIDE_
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
6
DRUG INTERACTIONS
......................................................................................................
10
DOSAGE AND ADMINISTRATION
...................................................................................
11
OVERDOSAGE
....................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
..............................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
............................................................................
15
DOSAGE FORMS, COMPOSITION AND
PACKAGING.................................................... 16
PART II: SCIENTIFIC INFORMATION
.............................................................................
17
PHARMACEUTICAL INFORMATION
....................................................................